Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06926933
NCT06926933Active, not recruitingPhase 4

An Open Label, Single-group, Multicenter Study on the Efficacy and Safety of Leuprolide Acetate 45 mg for Injectable Suspension-controlled Release in Subjects With Central (Gonadotropin-dependent) Precocious Puberty

HanAll BioPharma Co., Ltd.10 sites in 2 countries50 target enrollmentStarted: December 12, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Active, not recruiting
Enrollment
50
Locations
10
Primary Endpoint
The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.

Screening tests are performed after the subject agrees in writing to participate in the clinical trial, and subjects who meet the inclusion criteria and do not fall under the exclusion criteria are enrolled in the study. The target patients in this study are pediatric patients who have been diagnosed with CPP but have not yet received GnRH agonist treatment, and all subjects perform GnRH stimulation tests to confirm their CPP diagnosis.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
4 Years to 9 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Pubertal-type LH response following an abbreviated GnRH stimulation test before treatment initiation > 5 IU/L
  • •A subject manifested with central precocious puberty according to the following criteria Age : Boy (4 years of age or older ~ under 9 years of age) Girl (4 years of age or older ~ under 8 years of age) Tanner Stage : Level 2 or higher
  • •Based on baseline visit (Day 0), those under the age of 10 for boys and those under the age of 9 for girls
  • •Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP
  • •Children with a body weight of more than 20 kg at screening
  • •Children have a bone age that is ≥1 year older than their chronological age at screening
  • •A signed written consent form by a legal representative who has been informed about this study

Exclusion Criteria

  • •Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion
  • •Prior or current GnRH treatment for CPP
  • •Non-progressing isolated premature thelarche
  • •Presence of an unstable intracranial tumor or an intracranial tumor requiring neurosurgery or cerebral irradiation. Subjects with hamartomas not requiring surgery are eligible.
  • •Prior (within 12 weeks of Screening) use of medications
  • •Hormonal agonists (Estrogen, Progesterone, FSH, LH, Testosterone etc.)
  • •Hormonal antagonists (Anti-Estrogen agents, Anti-Androgen agents)
  • •Steroid use (except for mild topical steroids, oral steroids are allowed within 30 days)
  • •Herbal Medicines
  • •Prior or current therapy with growth hormone
  • •Major medical or psychiatric illness that could interfere with study visits
  • •Diagnosis of short stature (i.e. 2 standard deviations (SD) below the mean height for age or 3rd percentile for age)
  • •Pregnant or likely pregnant women (Positive urine pregnancy test), nursing women
  • •Known hypersensitivity to GnRH or related compounds
  • •Any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study
  • •Any other condition(s) which could significantly interfere with Protocol compliance
  • •Treatment with an investigational product within 5 half-lives of that product in prior clinical studies before the baseline visit (Day 0)
  • •Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions
  • •Prior (within 6 months of Baseline (Day 0)) or current use of medications that, per investigator opinion, have been associated with seizures or convulsions

Arms & Interventions

Eligard® 45 mg

Experimental

SC injection of study drug (45 mg of leuprolide acetate for injectable suspensions)

Intervention: Eligard® 45 mg (Drug)

Outcomes

Primary Outcomes

The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test

Time Frame: at week 24

Blood samples for serum LH concentrations (as appropriate) will be collected at the appropriate assessment times and analyzed by a central laboratory.

Secondary Outcomes

  • The percentage (%) of subjects with suppressed serum FSH (< 2.5 mIU/mL), estradiol (< 20 pg/mL, for girl) or testosterone (< 30 ng/dL, for boy)(at week 12, 24, 48, 72, 96)
  • The percentage of subject of Tanner stage (including menstruation)(at week 12, 24, 48, 72, 96)
  • Height velocity (growth rate)(at week 12, 24, 48, 72, 96)
  • The ratio of bone age and chronological age(at week 12, 24, 48, 72, 96)
  • The percentage (%) of subjects with suppressed serum LH concentrations (< 4 IU/L) 30-minutes post GnRH stimulation test(at week 12, 48, 72, 96)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (10)

Loading locations...

Similar Trials

Completed
Not Applicable
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® RegimenAtopic Dermatitis
NCT02073591Hyphens Pharma Pte Ltd58
Completed
Phase 4
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Juvenile Idiopathic Arthritis
NCT03301883Hoffmann-La Roche62
Recruiting
Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyMuscular Atrophy, Spinal
NCT05861999Hoffmann-La Roche28
Recruiting
Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyMuscular Atrophy, Spinal
NCT05861986Hoffmann-La Roche28
Completed
Phase 4
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb SpasticitySpasticity, Muscle
NCT03908580Medy-Tox120
Efficacy and Safety of Leuprolide Acetate... | Clinical Trial